Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India DCGI Warning Seen Hurting Sales Of Avandia

This article was originally published in PharmAsia News

Executive Summary

At least three of India's generics makers can expect reduced sales of one of their drugs in the wake of a warning by their country's regulator about rosiglitazone. The drug is the API of GlaxoSmithKline's Avandia for keeping blood sugar levels low in diabetes patients. The GSK drug and generics made by India's Sun Pharmaceuticals, Dr. Reddy's Laboratories, Torrent Pharmaceuticals and 30 other companies contribute to sales to as many as 10 million of the nation's 41 million diabetics. The Drugs Controller General of India ordered the makers of the drug to include a warning of risks to diabetics who also have heart problems. The drug has a competitor, ploglitazone, already made by several other Indian drug makers, so physicians already have begun switching their patients. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067588

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel